Skip to content

Prospective cohort study on quantitative MR evaluation during extension of heart failure therapy for patients with univentricular heart or after atrial swith operation with d-transposition of the great arteries

Prospective cohort study on quantitative MR evaluation during extension of heart failure therapy for patients with univentricular heart or after atrial swith operation with d-transposition of the great arteries - heart failure therapy in Fontan patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00035309
Enrollment
40
Registered
2024-10-17
Start date
2024-11-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.9

Interventions

Group 1: 20 patients each with Fontan circulation or atrial switch operation for d-TGA who are clinically stable but have experienced a worsening of the clinical situation within the last 6 months

Sponsors

Deutsches Herzzentrum München, Klinik für angeborene Herzfehler und Kinderkardiologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with Fontan circulation or atrial switch operation for d-TGA who are clinically stable but have experienced a worsening of their clinical condit ion within the last 6 months, necessitating an expansion of anti-congestive therapy from a clinical perspective. They should be in functional class 2 or 3 and, preferably, have shown an elevated end-diastolic pressure in the systemic ventricle during a cardiac catheterization within the last 24 months and/or a shift to a higher functional class

Exclusion criteria

Exclusion criteria: Excluded are patients in functional class 4 and patients with relevant pulmonary vascular pathology (transpulmonary gradient in Fontan patients = 4 mm Hg). Also excluded are all patients whose concomitant medication cannot be kept constant during the 6-week observation period. Additionally, patients with type I diabetes mellitus, patients under 18 years of age, as well as patients with atrial fibrillation and end-stage renal failure (eGFR < 30 ml/min/1.73 m²) will not be included

Design outcomes

Primary

MeasureTime frame
increase in cardiac output

Secondary

MeasureTime frame
increase of enddiastolic volume of systemic ventricle, ejection fraction of the systemic ventricle, serum NT-pro BNP

Countries

Germany

Contacts

Public ContactHeiko Stern

Deutsches Herzzentrum München, Klinik für angeborene Herzfehler und Kinderkardiologie

stern@kinderkardiologe-muenchen.de+491757424362

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026